Subrenal capsule grafting technology in human cancer modeling and translational cancer research

Differentiation

Volumn 91, Issue 4-5, 2016, Pages 15-19

  Wang, Yuzhuo ^a,b,c   Wang, Joy X ^a   Xue, Hui ^a,c   Lin, Dong ^a,c   Dong, Xin ^a,c   Gout, Peter W ^c   Gao, Xin ^d   Pang, Jun ^d  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer research; Patient derived xenografts; Prostate cancer; Subrenal capsule grafting

Indexed keywords

5' METHYLTHIOADENOSINE; ANTINEOPLASTIC AGENT; CISPLATIN; IRINOTECAN; TIOGUANINE;

CANCER GRAFT; CANCER GROWTH; CANCER MODEL; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CANCER TRANSPLANTATION; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HISTOPATHOLOGY; HUMAN; METASTASIS; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REPEATED DRUG DOSE; REVIEW; SKIN; SMALL CELL CARCINOMA; SUBRENAL CAPSULE GRAFTING; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG SCREENING; GENETICS; GROWTH, DEVELOPMENT AND AGING; KIDNEY; KIDNEY TRANSPLANTATION; MOUSE; NEOPLASMS; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MICE; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964951672     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2015.10.012     Document Type: Review

References (41)

1. Andersen, R.J., Mawji, N.R., et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:6 (2010), 535–546.
2. Beltran, H., Eng, K., et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1:4 (2015), 466–474.
3. Beltran, H., Rickman, D.S., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1:6 (2011), 487–495.
4. Bogden, A.E., The subrenal capsule assay (SRCA) and its predictive value in oncology. Ann. Chir. Gynaecol. Suppl. 199 (1985), 12–27.
5. Bogden, A.E., Haskell, P.M., et al. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp. Cell Biol. 47 4 (1979), 281–293.
6. Cheng, H., Clarkson, P.W., et al. Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma, 2010, 2010, 174528.
7. Choi, S.Y., Lin, D., et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv. Drug Deliv. Rev. 79–80 (2014), 222–237.
8. Collins, C.C., Volik, S.V., et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol. Cancer Ther. 11:3 (2012), 775–783.
9. Cunha, G.R., Alterations in the developmental properties of stroma during the development of the urogenital ridge into ductus deferens and uterus in embryonic and neonatal mice. J. Exp. Zool. 197 (1976), 375–388.
10. Cunha, G.R., Epithelial-stromal interactions in development of the urogenital tract. Int. Rev. Cytol. 47 (1976), 137–194.
11. Cunha, G.R., Baskin, L., Use of sub-renal capsule transplantation in developmental biology. Differentiation, 2015 this issue.
12. Cunha, G.R., Chung, L.W.K., et al. Hormone-induced morphogenesis and growth: Role of mesenchymal-epithelial interactions. Recent Prog. Horm. Res. 39 (1983), 559–598.
13. Cunha, G.R., Lung, B., et al. Role of the epithelial-stromal interaction during the development and expression of ovary-independent vaginal hyperplasia. Dev. Biol. 56 (1977), 52–67.
14. Cutz, J.C., Guan, J., et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin. Cancer Res. 12:13 (2006), 4043–4054.
15. Dong, X., Guan, J., et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16:5 (2010), 1442–1451.
16. Eirew, P., Steif, A., et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518:7539 (2015), 422–426.
17. Gout, P.W., Wang, Y., Drug sensitivity testing for personalized lung cancer therapy. J. Thorac. Dis. 4:1 (2012), 17–18.
18. Griffin, T.W., Bogden, A.E., et al. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 52:12 (1983), 2185–2192.
19. Jager, W., Xue, H., et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 6 (2015), 21522–21532.
20. Kortmann, U., McAlpine, J.N., et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17:4 (2011), 783–791.
21. Lee, C.H., Xue, H., et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol. Oncol. 96:1 (2005), 48–55.
22. Lin, D., Bayani, J., et al. Development of metastatic and non-metastatic tumor lines from a patient prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. Prostate 70 (2010), 1636–1644.
23. Lin, D., Watahiki, A., et al. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res. 68:11 (2008), 4352–4359.
24. Lin, D., Wyatt, A.W., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74:4 (2014), 1272–1283.
25. Lin, D., Xue, H., et al. Next generation patient-derived prostate cancer xenograft models. Asian J. Androl. 16 (2014), 407–412.
26. Maenpaa, J., Gronroos, M., et al. Subrenal capsule assay in choosing cytostatics for gynaecological tumours. Ann. Chir. Gynaecol. Suppl. 199 (1985), 28–30.
27. McPherson, S.J., Hussain, S., et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc. Natl. Acad. Sci. USA 107:7 (2010), 3123–3128.
28. Ott, C.E., Knox, F.G., Tissue pressures and fluid dynamics in the kidney. Fed. Proc. 35:8 (1976), 1972–1975.
29. Press, J.Z., Kenyon, J.A., et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol. Oncol. 110:2 (2008), 256–264.
30. Priolo, C., Agostini, M., et al. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am. J. Pathol. 176:4 (2010), 1901–1913.
31. Qu, S., Wang, K., et al. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol. Oncol. 8:2 (2014), 311–322.
32. Robertson, N.J., Fairchild, P.J., et al. Ectopic transplantation of tissues under the kidney capsule. Methods Mol. Biol. 380 (2007), 347–353.
33. Sharpless, N.E., Depinho, R.A., The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5:9 (2006), 741–754.
34. Tung, W.L., Wang, Y., et al. Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate 71:7 (2011), 675–681.
35. van Weerden, W.M., de Ridder, C.M., et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 149:3 (1996), 1055–1062.
36. Voskoglou-Nomikos, T., Pater, J.L., et al. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9:11 (2003), 4227–4239.
37. Wang, Y., Revelo, M.P., et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64:2 (2005), 149–159.
38. Wang, Y., Xue, H., et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab. Investig. 85:11 (2005), 1392–1404.
39. Watahiki, A., Wang, Y., et al. MicroRNAs associated with metastatic prostate cancer. PLoS One, 6(9), 2011, e24950.
40. Watahiki, A., Wang, Y., et al. Establishment and characterization of a novel pancreatic cancer tissue xenograft model. Proc. Am. Assoc. Cancer Res., 47, 2006 Abstract #5106, 1198.
41. Zhao, H., Nolley, R., et al. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am. J. Pathol. 177:1 (2010), 229–239.